Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Moderna’s (MRNA) Q4 2023 earnings results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) reported a sharp decline in revenues and earnings for the fourth quarter of 2023.
Net income fell to $217 million or $0.55 per share in the December quarter from $1.47 billion or $3.61 per share in the same period of fiscal 2022.
The bottom line was negatively impacted by a 45% fall in revenues to $2.81 billion. There was a 43% drop in product revenues. The management reaffirmed its full-year 2024 product sales guidance at approximately $4 billion.
“We look forward to the anticipated approvals of our RSV vaccine beginning in the first half of the year. With multiple upcoming Phase 3 data readouts in 2024, we remain focused on commercial execution and continued investment in our pipeline with financial discipline,” said Moderna’s CEO Stéphane Bancel.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a positive year, what’s in the cards for Electronic Arts (EA) in FY25
Electronic Arts (NASDAQ: EA) ended fiscal 2024 on a mixed note, reporting lower revenues and improved bottom-line performance for the fourth quarter. The stock declined following the announcement as earnings
A look at how Disney’s (DIS) entertainment business performed in Q2 2024
Shares of the Walt Disney Company (NYSE: DIS) stayed green on Wednesday. The stock has gained 16% year-to-date. The company recorded revenue and earnings growth for the second quarter of
Uber Technologies reports wider loss for Q1 2024; revenue up 15%
Uber Technologies, Inc. (NYSE: UBER) on Wednesday reported a wider net loss for the first quarter of 2024. Revenues of the ride-sharing giant increased 15% during the three months. Net